How do we separate proven findings from marketing hype?
We systematically analyze medical literature to isolate high-confidence clinical findings from unproven claims. Our evidence evaluation considers study design quality, sample size, consistency of results, biological plausibility, and reproducibility — including the instructive null results.
Understanding medical research can feel overwhelming, but a few key principles help distinguish strong evidence from weak:
Luther Terry's advisory committee links smoking to lung cancer and chronic bronchitis — respiratory public health's founding document.
Inhaled corticosteroids and bronchodilators replace oral steroids and injections — targeted lung therapy begins.
NAC proven to reduce COPD exacerbations by thinning mucus as an adjunctive therapy.
Vitamin D supplementation shown to reduce respiratory tract infections in deficient patients.
Omega-3s confirmed to help balance airway inflammatory markers — while vitamin D trials in replete populations come back null, establishing the deficiency-corrector framing.
Severe-asthma biologics, COPD bronchoscopic options, and low-dose CT screening for eligible smokers — while cessation remains the single most powerful lung intervention.
POPULATION · 5,887 smokers with early COPD, 5 years
FINDING · Smoking cessation produced a substantially slower rate of FEV1 decline versus continued smoking — the only intervention proven to alter COPD's course.
LIMITATION · Benefit required sustained cessation; quitters averaged modest weight gain. The inhaled-ipratropium arm showed no long-term FEV1 benefit.
POPULATION · 644 community-dwelling adults, monthly 60,000 IU vitamin D or placebo, 1 year
FINDING · No significant reduction in acute respiratory infection — in a largely vitamin D-replete population given bolus dosing.
LIMITATION · Monthly bolus dosing is now known to be inferior to daily supplementation (the osteoporosis literature's lesson), and the replete population defines the boundary: the benefit lives in deficiency correction.
POPULATION · 150 adults with mild persistent asthma
FINDING · Reduced airway inflammatory markers and decreased leukotriene synthesis by 30%.
LIMITATION · Short 3-month duration; effect on severe asthma or COPD unknown. Used as adjunct to standard inhalers.
POPULATION · 400 adults with COPD/Chronic Bronchitis
FINDING · Reduced acute exacerbations by 35% over 6 months by thinning mucus secretions.
LIMITATION · Effect less pronounced in active smokers. Patients remained on their standard bronchodilator therapy.